Patrick Ryan, former Abbott Vascular Devices divisional vice president for North Asia, will pick up the COO reins at Alphatec Holdings, according to an April 25 company announcement.
Patrick Ryan New Alphatec COO
1 min read Premium comments
Under Ryan’s leadership that division of Abbott had annual revenues of $200 million. Ryan also held three other senior roles in operations at Abbott—divisional vice-president for Canada and Latin America for the firm’s Vascular Division, divisional vice president, Worldwide Operations, and divisional vice president of Operations for Cardiac Therapies.
Before joining Abbott, Ryan held several positions with Guidant Corporation including vice president and managing director, Guidant Ireland. Ryan served 14 years in the United States Navy. He received his MS in Petroleum Management from the University of Kansas, Lawrence, and his BS from the United States Naval Academy.
Alphatec Holdings is a medical device company that designs, develops, manufactures, and markets products for the surgical treatment of spine disorders. The company’s emphasis is on the aging spine.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.